Copyright
©The Author(s) 2005.
World J Gastroenterol. Nov 14, 2005; 11(42): 6582-6586
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6582
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6582
Table 1 Tumor mass of three groups treated with Ad-p27kip1, Ad-LacZ (1.0×1010 pfu) or PBS at wk 4
| Groups(%) | Tumor mass (g) | IR | |||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | mean±SD | ||
| Control | 1.02 | 0.93 | 1.31 | 1.47 | 0.86 | 1.63 | 0.95 | 1.17±0.30 | |
| Ad-LacZ | 0.72 | 1.36 | 1.12 | 0.87 | 0.92 | 1.23 | 0.85 | 1.00±0.23 | |
| Ad-p27kip1 | 0.32 | 0.46 | 0.35 | 0.43 | 0.57 | 0.38 | 0.40 | 0.42±0.08b | 64.1 |
-
Citation: Zhang WG, Wu QM, Yu JP, Tong Q, Xie GJ, Wang XH, Li SB. Adenovirus expressing p27
kip1 suppresses growth of established esophageal carcinoma xenografts. World J Gastroenterol 2005; 11(42): 6582-6586 - URL: https://www.wjgnet.com/1007-9327/full/v11/i42/6582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i42.6582